EUVIMEDEUVIMED entdecken
Open Access

Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage

Fabio Catalano, Eva C Vlaar, Zina Dammou, Drosos Katsavelis, Tessa F Huizer, Giacomo Zundo, Marianne Hoogeveen-Westerveld, Esmeralda Oussoren, Hannerieke J M P van den Hout, Gerben Schaaf, Karin Pike-Overzet, Frank J T Staal und 2 weitere

Human Gene Therapy · 2024

DOI: 10.1089/hum.2023.177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2024. Verfasst von Fabio Catalano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Mucopolysaccharidosis II, Iduronate Sulfatase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deficiency of iduronate 2-sulfatase (IDS) causes Mucopolysaccharidosis type II (MPS II), a lysosomal storage disorder characterized by systemic accumulation of glycosaminoglycans (GAGs), leading to a devastating cognitive decline and life-threatening respiratory and cardiac complications. We previously found that hematopoietic stem and progenitor cell-mediated lentiviral gene therapy (HSPC-LVGT) employing tagged IDS with insulin-like growth factor 2 (IGF2) or ApoE2, but not receptor-associated protein minimal peptide (RAP12x2), efficiently prevented brain pathology in a murine model of MPS II. In this study, we report on the effects of HSPC-LVGT on peripheral pathology and we analyzed IDS biodistribution. We found that HSPC-LVGT with all vectors completely corrected GAG accumulation and lysosomal pathology in liver, spleen, kidney, tracheal mucosa, and heart valves. Full correction of tunica media of the great heart vessels was achieved only with IDS.IGF2co gene therapy, while the other vectors provided near complete (IDS.ApoE2co) or no (IDSco and IDS.RAP12x2co) correction. In contrast, tracheal, epiphyseal, and articular cartilage remained largely uncorrected by all vectors tested. These efficacies were closely matched by IDS protein levels following HSPC-LVGT. Our results demonstrate the capability of HSPC-LVGT to correct pathology in tissues of high clinical relevance, including those of the heart and respiratory system, while challenges remain for the correction of cartilage pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IIIduronate SulfataseAnimalsMiceIduronic AcidLentivirusTissue DistributionGenetic TherapyCartilage

Stichwörter der Autor:innen

ApoE2Hunter syndromeIDSIGF2Mucopolysaccharidosis type IIRAPlentiviral gene therapymacrophage engraftment

Substanzen

Iduronic AcidIduronate Sulfatase

Autor:innen und Institutionen

  • Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Department of Pediatrics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: W W M Pim Pijnappel

Zitieren

APA

Catalano, F., Vlaar, E. C., Dammou, Z., Katsavelis, D., Huizer, T. F., Zundo, G., Hoogeveen-Westerveld, M., Oussoren, E., van den Hout, H. J. M. P., Schaaf, G., Pike-Overzet, K., Staal, F. J. T., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2024). Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage. Human Gene Therapy. https://doi.org/10.1089/hum.2023.177

Vancouver

Catalano F, Vlaar EC, Dammou Z, Katsavelis D, Huizer TF, Zundo G, et al. Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage. Human Gene Therapy. 2024. doi:10.1089/hum.2023.177

BibTeX
@article{Catalano2024,
  author = {Catalano, Fabio and Vlaar, Eva C and Dammou, Zina and Katsavelis, Drosos and Huizer, Tessa F and Zundo, Giacomo and Hoogeveen-Westerveld, Marianne and Oussoren, Esmeralda and van den Hout, Hannerieke J M P and Schaaf, Gerben and Pike-Overzet, Karin and Staal, Frank J T and van der Ploeg, Ans T and Pijnappel, W W M Pim},
  title = {Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage},
  journal = {Human Gene Therapy},
  year = {2024},
  doi = {10.1089/hum.2023.177}
}
Kostenlos starten →